Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

S.-B. Kim, D.J. Maslyar, R. Dent, S.-A. Im, M. Espié, S. Blau, A.R. Tan, S. Isakoff, M. Oliveira, C. Saura, M.J. Wongchenko, A.V. Kapp, W.Y. Chan, S.M. Singel, J. Baselga, S.-B. Kim, K.S. Lee, S.-A. Im, M. Espié, H.-C. WangS. Blau, R. Dent, A. Tan, J.H. Sohn, M. De Laurentiis, L.G. Estevez, C.-S. Huang, G. Romieu, M. Velez, R. Villanueva, P.F. Conte, S. Dakhil, M. Debled, A.G. Martin, S. Hurvitz, J.H. Kim, C. Levy, M. Oliveira, P.S. Rovira, J.H. Seo, V. Valero, G. Vidal, A. Wong, M.A.K. Allison, R. Figlin, D. Chan, S.-C. Chen, Y.-H. Chen, M. Cobleigh, F. De Braud, L. Dirix, V. Hansen, A.H. Bessard, N. Iannotti, S. Isakoff, W. Lawler, A. Montaño, M. Salkini, L. Seigel

Research output: Contribution to journalArticlepeer-review

Original languageUndefined/Unknown
Pages (from-to)1360-1372
Number of pages13
JournalThe Lancet Oncology
Issue number10
Publication statusPublished - 2017

Cite this